China’s antibody boom: from copycat to innovation leader

adicionou um novo artigo Sağlıklı Yaşam

2026-04-06 10:06:31 -

For years, China’s biotech sector was known for making cheaper versions of Western drugs. Not anymore. The country is now a hotbed of novel antibody discovery, with homegrown PD‑1 inhibitors competing head‑to‑head with Merck’s Keytruda. The China antibodies market report by MRFR shows the market is already $22.84 billion and will hit $94 billion by 2035, growing at a...

0 Comentários 0 Compartilhamentos 55 Visualizações 0 Anterior